Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

REGISTER for free or LOG IN to view this content

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Clinical Cardiology

Clinical Pharma

Lipids

Prevention

Coronary

ACS/AMI

CAD Pharma

Presentation

ESC 2017

Up Next

Presentation ESC 2017

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

Presenter: Martin J. Holzmann

August 28, 2017

More slides +

Presentation ESC 2017

The Viborg Vascular (VIVA) Randomised Screening Trial

Presenter: Jes Lindholt

August 29, 2017

Presentation

Spontaneous Coronary Artery Dissection: Clinical Outcomes and Risk of Recurrence

August 29, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.